Drug intelligence / Profile preview

EDP1908

Development stage: Preclinical
Lead developer: Evelo Biosciences
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EDP1908 is an investigational, orally delivered extracellular vesicle-based therapeutic being developed by Evelo Biosciences for the treatment of cancer. [1, 5] It is designed to act locally on the small intestinal axis (SINTAX) to stimulate a systemic anti-tumor immune response without being absorbed into the rest of the body. [1, 5, 9] Preclinical studies have shown that EDP1908 can activate immune cells such as lymphocytes and dendritic cells within the tumor microenvironment. [1, 5] In December 2020, Evelo prioritized EDP1908 as its lead oncology candidate over a previous candidate, EDP1503, due to superior preclinical activity. [1]

Beyond the preview

Go deeper on EDP1908.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP1908.

Explore the full profile